Trial Profile
Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer.
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 18 Apr 2023
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Temsirolimus (Primary) ; Carboplatin; Paclitaxel; Sorafenib
- Indications Cancer; Solid tumours
- Focus Adverse reactions
- 05 Apr 2023 Planned End Date changed from 1 Dec 2022 to 30 Apr 2024.
- 05 Apr 2023 Planned primary completion date changed from 1 Dec 2022 to 30 Apr 2024.
- 26 Apr 2022 Planned End Date changed from 1 Dec 2021 to 1 Dec 2022.